| Patient | Edward W. Brooke |
|---|---|
| Date of birth | 1942-10-26 |
| Identifiers | MRN HR-ML014-SYN; SSN (made up) 000-14-5063 |
| Document date | 2026-02-10 |
| Author | Howard Bellamy, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week follow-up on tamoxifen; bone density results; medical oncology seen today. [S]
Mr. Brooke returns four weeks after his first visit. He has taken tamoxifen 20 mg every day for fifteen weeks and keeps the bottle by his toothbrush. He has mild hot flashes two or three times a week, mostly at night, which do not stop him sleeping. He has had no leg swelling or pain, chest pain, or breathlessness, and no change in vision. The mastectomy scars are comfortable and he has full movement of the right shoulder, with no arm swelling. He had his DXA scan this morning and saw Dr. Cho of medical oncology, who has taken over his tamoxifen and sent a germline genetic test today. He starts vitamin D today for the low level found at the first visit. He walks most days. [S]
| Element | Detail |
|---|---|
| Tamoxifen | Fifteen weeks; no missed doses |
| Side effects | Mild night hot flashes; no clot symptoms or visual change |
| Surgical sites | Comfortable; full right shoulder movement; no arm swelling |
| Coordination | Medical oncology seen today; germline test sent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue, weight loss, or night sweats |
| Endocrine | Positive | Mild hot flashes at night |
| Cardiovascular | Negative | No chest pain or leg swelling or pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain; full shoulder movement |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2025-10-28 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 183 | cm | S |
| 2026-02-10 | Body weight | 81.8 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 68 | /min | S |
| 2026-02-10 | Respiratory rate | 14 | /min | S |
| 2026-02-10 | Body temperature | 36.7 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | DXA Femur [T-score] Bone density | -1.2 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | DXA Lumbar spine [T-score] Bone density | -0.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Normal | S |
| 2026-02-10 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-02-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Chest wall | Healed transverse mastectomy scars on both sides; no nodule or skin change |
| Lymph nodes | Right axillary scar healed; no axillary, supraclavicular, or cervical nodes on either side |
| Extremities | Upper arm circumference 31 cm on both sides; no calf swelling or tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed | C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed | Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed | Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed | Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and examination of both sides of the chest wall and both axillae | Every 3 to 6 months for 3 years | Completed today | No nodule, skin change, or nodes |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit after axillary surgery | Completed today | Arm circumferences equal at 31 cm; skin care and early reporting reviewed |
| Medication safety | Venous thromboembolism symptoms on tamoxifen | Every visit on tamoxifen | Completed today | No leg swelling or pain, chest pain, or breathlessness |
| Medication safety | Hot flashes on tamoxifen | Every visit on tamoxifen | Completed today | Mild, at night; no treatment needed. Paroxetine, fluoxetine, and bupropion are to be avoided because they block the activation of tamoxifen |
| Medication safety | Sexual side effects of tamoxifen (libido, erectile function) | Every visit on tamoxifen | Deferred | Not asked today, a deviation from the protocol; the visit was taken up by the bone density and consultation results. To be asked at the next visit |
| Medication safety | Adherence to tamoxifen | Every visit on tamoxifen | Completed today | No missed doses; pill bottle kept by his toothbrush |
| Survey | Distress and depression screen (PHQ-2) | Every visit | Completed today | PHQ-2 score 0 |
| Imaging | Bone density (DXA) | Baseline on hormone therapy, then every 2 years | Completed today | Femoral neck T-score -1.2 (low bone mass); lumbar spine -0.4 (normal) |
| Laboratory | 25-hydroxyvitamin D | At baseline, then three months after starting a supplement | Due | 24 ng/mL at the first visit; recheck in three months |
| Laboratory | Germline multigene panel testing | Once, for every man with breast cancer | Ordered | Blood sent today by medical oncology; genetic counseling before and after the result |
| Referral | Medical oncology | Once, then as the oncologist advises | Completed today | Seen today; recommendations in the consultation note |
| Imaging | Breast imaging (mammography) | Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variant | Not indicated | Both breasts were removed; there is no breast tissue to image |
| Laboratory | Routine blood tests, tumor markers, and CT, bone scan, or PET | Not recommended without symptoms in stage I to III disease | Not indicated | No symptoms suggesting recurrence |
| Self-management | Physical activity | Every visit | Completed today | Walking most days; light weights added for bone health |
Goal progress:
Guideline basis: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Primary care review in three months with a vitamin D recheck. Genetic counseling appointment for the result. Medical oncology every six months. Next scheduled visit 2026-05-12: three-month follow-up: germline result, tamoxifen side effects and adherence, vitamin D recheck. [S]